NYSE:NUVB Nuvation Bio (NUVB) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free NUVB Stock Alerts $2.69 +0.01 (+0.37%) (As of 08:00 AM ET) Add Compare Share Share Today's Range$2.69▼$2.6950-Day Range$1.66▼$3.9652-Week Range$0.95▼$4.16Volume986 shsAverage Volume1.18 million shsMarket Capitalization$586.55 millionP/E RatioN/ADividend YieldN/APrice Target$6.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nuvation Bio alerts: Email Address Nuvation Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside146.3% Upside$6.60 Price TargetShort InterestHealthy2.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.35) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.77 out of 5 starsMedical Sector216th out of 910 stocksPharmaceutical Preparations Industry84th out of 423 stocks 4.5 Analyst's Opinion Consensus RatingNuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvation Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.10% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuvation Bio has recently increased by 6.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVB. Previous Next 3.1 News and Social Media Coverage News SentimentNuvation Bio has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Nuvation Bio this week, compared to 1 article on an average week.Search Interest15 people have searched for NUVB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows21 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 2,000% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have not sold or bought any company stock.Percentage Held by Insiders36.09% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nuvation Bio are expected to decrease in the coming year, from ($0.35) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -7.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -7.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Nuvation Bio Stock (NYSE:NUVB)Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Read More NUVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVB Stock News HeadlinesApril 21, 2024 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Trading Up 5%April 19, 2024 | americanbankingnews.comRoyal Bank of Canada Increases Nuvation Bio (NYSE:NUVB) Price Target to $5.00April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 18, 2024 | americanbankingnews.comNuvation Bio (NYSE:NUVB) Shares Gap Up Following Analyst UpgradeApril 17, 2024 | benzinga.comNuvation Bio Stock (NYSE:NUVB), Analyst Ratings, Price Targets, PredictionsApril 13, 2024 | markets.businessinsider.comStrategic Acquisition Bolsters Nuvation Bio’s Growth Potential and Pipeline ProspectsApril 10, 2024 | businesswire.comNuvation Bio Completes Acquisition of AnHeart TherapeuticsMarch 31, 2024 | seekingalpha.comWeek In Review: AriBio Sells China Rights To Alzheimer's Candidate In $770M DealApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 28, 2024 | businesswire.comNuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial OfficerMarch 27, 2024 | msn.comBTIG upgrades Nuvation to buy, cites AnHeart acquisitionMarch 27, 2024 | msn.comNuvation Bio continues to surge as more upgrades follow after AnHeart dealMarch 20, 2024 | finance.yahoo.comNUVB Apr 2024 2.000 putMarch 16, 2024 | finance.yahoo.comNUVB Apr 2024 0.500 callMarch 15, 2024 | msn.comNuvation Bio begins subject dosing in Phase I/II solid tumour trialMarch 14, 2024 | businesswire.comNuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid TumorsMarch 14, 2024 | baystreet.caBiotech Sector Advances in Pancreatic Cancer ResearchMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nuvation Bio Amid Strong Financial Performance and Promising Clinical ProgressFebruary 29, 2024 | finance.yahoo.comNuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | businesswire.comNuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 17, 2024 | finance.yahoo.comOwning 46% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB),January 8, 2024 | msn.comFDA clears Nuvation to begin Phase 1/2 study for oncology drugJanuary 8, 2024 | finance.yahoo.comNuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid TumorsJanuary 8, 2024 | finance.yahoo.comNuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of DirectorsNovember 13, 2023 | finance.yahoo.comNuvation Bio Announces Departure of Chief Financial OfficerNovember 4, 2023 | benzinga.comNuvation Bio Stock (NYSE:NUVB) Earnings Dates and Earning CallsNovember 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Nuvation Bio (NUVB) and Generation Bio (GBIO)See More Headlines Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/22/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NUVB CUSIPN/A CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Target$6.60 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+146.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-12.21% Return on Assets-11.89% Debt Debt-to-Equity RatioN/A Current Ratio44.11 Quick Ratio44.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book0.97Miscellaneous Outstanding Shares218,046,000Free Float139,353,000Market Cap$584.36 million OptionableOptionable Beta1.37 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. David T. Hung M.D. (Age 66)Founder, President, CEO & Director Comp: $944.51kDr. David C. Hanley Ph.D. (Age 54)Chief Technical Operations Officer Comp: $586.04kMr. Moses Makunje (Age 45)Principal Accounting Officer & Principal Financial Officer Dr. Gary Hattersley Ph.D. (Age 57)Chief Scientific Officer Comp: $687.88kMs. Stacy Markel (Age 59)Chief People Officer Ms. Kerry A. Wentworth (Age 51)Chief Regulatory Officer Dr. David Liu M.D. (Age 54)Ph.D., Chief Medical Officer Ms. Colleen SjogrenChief Commercial OfficerMore ExecutivesKey CompetitorsLyell ImmunopharmaNASDAQ:LYELAstria TherapeuticsNASDAQ:ATXSOlema PharmaceuticalsNASDAQ:OLMAMineralys TherapeuticsNASDAQ:MLYSVerve TherapeuticsNASDAQ:VERVView All CompetitorsInstitutional OwnershipOctagon Capital Advisors LPBought 1,000,000 shares on 2/15/2024Ownership: 0.457%Beacon Pointe Advisors LLCBought 21,700 shares on 2/8/2024Ownership: 0.010%Gladius Capital Management LPBought 14,885 shares on 2/7/2024Ownership: 0.014%Intellectus Partners LLCSold 32,996 shares on 2/5/2024Ownership: 0.083%Marquette Asset Management LLCBought 46,369 shares on 2/2/2024Ownership: 0.051%View All Institutional Transactions NUVB Stock Analysis - Frequently Asked Questions Should I buy or sell Nuvation Bio stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NUVB shares. View NUVB analyst ratings or view top-rated stocks. What is Nuvation Bio's stock price target for 2024? 5 brokers have issued 1-year price objectives for Nuvation Bio's shares. Their NUVB share price targets range from $5.00 to $10.00. On average, they predict the company's share price to reach $6.60 in the next twelve months. This suggests a possible upside of 146.3% from the stock's current price. View analysts price targets for NUVB or view top-rated stocks among Wall Street analysts. How have NUVB shares performed in 2024? Nuvation Bio's stock was trading at $1.51 at the beginning of the year. Since then, NUVB stock has increased by 77.5% and is now trading at $2.68. View the best growth stocks for 2024 here. When is Nuvation Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NUVB earnings forecast. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04. What ETFs hold Nuvation Bio's stock? ETFs with the largest weight of Nuvation Bio (NYSE:NUVB) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NUVB) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
